Global InformationYu Baofa information
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
Dr. Yu Baofa | |
|---|---|
| Born | 1958 (age 65–66) Jinan, China |
| Nationality | Chinese |
| Education | Binzhou Medical College, Peking Union Medical College |
| Occupation | Oncologist |
| Medical career | |
| Research | Intratumoral Cancer Therapy |
| Notable works | Ultra Minimum Incision Personalized Intra-Tumoral Chemo-Immuno (UMIPIC) Therapy. |
| Website | www |
Yu Baofa (Chinese: 于保法; pinyin: Yú Bǎofǎ; born in 1958) is a Chinese oncologist and researcher in intratumoral cancer therapy and drug development.[1] He is the Founder, CEO and Chairman of Baofa Cancer Hospital Network China in Jinan, Beijing and Dongping.[2] He also developed Ultra Minimum Incision Personalized Intra-Tumoral Chemo-Immuno (UMIPIC) Therapy.[3][4]
- ^ "Professor devoted to medical research and treatmentn". www.chinadaily.com.cn. Retrieved 3 March 2019.
- ^ "Meet Dr. Baofa Yu". Baofa Immunotherapy, LLC. Retrieved 3 March 2019.
- ^ Yu, Baofa; Lu, Yuanfei; Gao, Feng; Jing, Peng; Wei, Han; Zhang, Peicheng; Liu, Guoliang; Ru, Ning; Cui, Guanghui; Xu, Xinhai; Sun, Chenglin; Guan, Changjiang; Che, Yebing; Wu, Yingli; Ma, Zhenlu; Fu, Qiang; Liu, Jian; Wang, Huan-You (2015). "Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy". Lung Cancer: Targets and Therapy. 6: 1–11. doi:10.2147/LCTT.S70679. PMC 5217516. PMID 28210146.
- ^ Gao, Feng; Jing, Peng; Liu, Jian; Lu, Yuanfei; Zhang, Peicheng; Han, Wei; Liu, Guoliang; Ru, Ning; Cui, Guanghui; Sun, Chenglin; Che, Yebing; Zhang, Huaming; Hu, Qnglong; Wang, Huan-You; Wu, Yingli; Guan, Changjiang; Fu, Qiang; Ma, Zhenlu; Yu, Baofa (2015). "Hapten-enhanced overall survival time in advanced hepatocellular carcinoma by ultro-minimum incision personalized intratumoral chemoimmunotherapy". Journal of Hepatocellular Carcinoma. 2: 57–68. doi:10.2147/JHC.S80756. PMC 4918285. PMID 27508195.